RXRXRECURSION PHARMACEUTICALS, ...

Nasdaq recursion.com


$ 8.35 $ 0.68 (8.85 %)    

Friday, 12-Jul-2024 15:59:58 EDT
QQQ $ 494.79 $ 2.89 (0.59 %)
DIA $ 400.37 $ 2.69 (0.68 %)
SPY $ 559.91 $ 3.51 (0.63 %)
TLT $ 93.88 $ 0.40 (0.43 %)
GLD $ 223.10 $ -0.14 (-0.06 %)
$ 8.36
$ 7.81
$ 0.00 x 0
$ 8.35 x 985
$ 7.80 - $ 8.60
$ 4.97 - $ 16.75
10,190,691
na
1.97B
$ 2.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 02-27-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-23-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 keybanc-maintains-overweight-on-recursion-pharmaceuticals-lowers-price-target-to-12

Keybanc analyst Scott Schoenhaus maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price ta...

 why-recursion-pharmaceuticals-stock-is-tumbling-thursday

Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwri...

Core News & Articles
Market-Moving News for June 27th
06/27/2024 12:37:40

CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Prop...

 recursion-pharmaceuticals-stock-is-diving-wednesday-whats-going-on

After the market close on Wednesday, Recursion said it intends to offer and sell $200 million worth of its common stock in an u...

 recursion-pharmaceuticals-stock-is-moving-tuesday-whats-happening

Shares of clinical stage biotech company Recursion Pharmaceuticals Inc (NASDAQ:RXRX) are trading higher Tuesday. The company...

 needham-reiterates-buy-on-recursion-pharmaceuticals-maintains-17-price-target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.

 whats-going-on-with-recursion-pharmaceuticals-stock-monday

Recursion Pharmaceuticals shares traded higher Monday after the company provided updated guidance and partnership updates at it...

 helix-recursion-pharmaceuticals-partner-to-drive-drug-discovery-innovation-through-clinico-genomic-data

Access to Helix's large-scale clinico-genomic data to drive creation and training of AI modelsHelix, a leading population g...

 recursion-eyes-guidance-on-seven-clinical-readouts-within-18-months-and-shares-partnership-updates-at-co-download-day

Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to ad...